Genomic Medicine Sweden
| Reference number | |
| Coordinator | Region Skåne - Skånes universitetssjukhus SUS |
| Funding from Vinnova | SEK 74 773 089 |
| Project duration | November 2018 - December 2022 |
| Status | Completed |
| Venture | 2017-01599-en |
Important results from the project
Genomic Medicine Sweden (GMS) is a national effort to ensure that patients in Sweden have equal access to genetic analysis to enable better diagnostics and more personalized care, treatment and prevention. Since the start in 2018, GMS has built a national and regional organization for coordination and harmonization to facilitate the introduction of precision medicine in an equitable manner across Sweden. Broad genetic analyses have been developed and introduced in routine healthcare and a national genomics platform has been established to share data.
Expected long term effects
GMS is a strong voice for precision medicine and stressing the barriers that need to be addressed nationally and regionally. A government committee review on the secondary use of health data is an important outcome where GMS has played a key role. Broad genomics has been introduced in routine care across Sweden in different diagnostic areas, as a basis for personalized care and treatment. GMS national studies pave the way for the next generation of precision diagnostics. International and national collaborations enable e.g. national clinical studies.
Approach and implementation
A success factor has been the national steering group, with R&D directors from the regions, deans from the universities and representatives of patient organizations and the life science industry, which anchored the project regionally and nationally. Another such factor has been the involvement of clinically active people in the different working committees, which has created relevance and demand for the new diagnostic tools developed. Legal barriers have posed significant challenges.